eflepedocokin alfa: Clinical Trials

5 trials of eflepedocokin alfa, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 recruiting, 1 terminated, 1 withdrawn. 5 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Recruiting 1, Terminated 1, Withdrawn 1
Phase 12Completed 2

Follow eflepedocokin alfa: new trials by email Literature Review of eflepedocokin alfa trials Research Report on eflepedocokin alfa

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial
IL-22, Prednisone, Acamprosate - Alcohol-associated Hepatitis
Phase 2RecruitingSamer Gawrieh2162026-01-272026-07-15
Study of F-652 in Subjects With Corona Virus Disease 2019 (COVID-19) Pneumonia
F-652, Placebo - COVID-19 Pneumonia
Phase 2WithdrawnEVIVE Biotechnology2022-04-082023-10-02
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
F-652, Placebo - Covid19
Phase 2TerminatedEVIVE Biotechnology12021-01-262023-12-21
Study of IL-22 IgG2-Fc (F-652) for Subjects With Grade II-IV Lower GI aGVHD
Recombinant Human Interleukin-22 IgG2-Fc (F-652), Systemic Corticosteroids - Acute Graft vs Host Disease
Phase 1 / Phase 2CompletedEVIVE Biotechnology302016-05-122021-07-22
Use of F-652 in Patients With Alcoholic Hepatitis
F-652 - Alcoholic Hepatitis
Phase 1 / Phase 2CompletedMayo Clinic182016-02-012019-09-09

Conditions studied

COVID-19 (1)  ·  Hepatitis, Alcoholic (1)

Sponsors

EVIVE Biotechnology (3)  ·  Mayo Clinic (1)  ·  Samer Gawrieh (1)

Countries

United States (4)

Top investigators

Christine M Bojanowski, MD (1)  ·  Doris Ponce, M.D. (1)  ·  Vijay Shah, MD (1)

Results publications

PMID 36399701, PMID 37011138

NIH funding

U24AA026969 (1)